These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36662166)

  • 1. Expected Benefits and Budget Impact From a Microsimulation Model Support the Prioritization and Implementation of Fracture Liaison Services.
    Pinedo-Villanueva R; Burn E; Maronga C; Cooper C; Javaid MK
    J Bone Miner Res; 2023 Apr; 38(4):499-511. PubMed ID: 36662166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision.
    McLellan AR; Wolowacz SE; Zimovetz EA; Beard SM; Lock S; McCrink L; Adekunle F; Roberts D
    Osteoporos Int; 2011 Jul; 22(7):2083-98. PubMed ID: 21607809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
    Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
    Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of fracture liaison services: a Markov model using Dutch real-world data.
    Li N; van den Bergh JP; Boonen A; Wyers CE; Bours SPG; Hiligsmann M
    Osteoporos Int; 2024 Feb; 35(2):293-307. PubMed ID: 37783759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a fracture liaison service--a real-world evaluation after 6 years of service provision.
    Yong JH; Masucci L; Hoch JS; Sujic R; Beaton D
    Osteoporos Int; 2016 Jan; 27(1):231-40. PubMed ID: 26275439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Recurrent Fracture Risk and Implementation of Fracture Liaison Services in Four Swedish Hospitals: A Cohort Study.
    Axelsson KF; Johansson H; Lundh D; Möller M; Lorentzon M
    J Bone Miner Res; 2020 Jul; 35(7):1216-1223. PubMed ID: 32097504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to initiate and develop Fracture Liaison Services (FLS). Recommendations from the IOF Capture the Fracture® FLS Mentors in Brazil.
    Stolnicki B; Inácio AM; Tutiya KK; Vieira LFT; Javaid MK; Caló M
    Arch Osteoporos; 2022 Apr; 17(1):63. PubMed ID: 35411442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Healthcare Trajectory and its Impact on the Cost-Effectiveness of Fracture Liaison Services.
    Senay A; Fernandes JC; Delisle J; Morin SN; Dragomir A; Nazha S; Perreault S
    J Bone Miner Res; 2021 Mar; 36(3):459-468. PubMed ID: 33484586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature.
    Wu CH; Kao IJ; Hung WC; Lin SC; Liu HC; Hsieh MH; Bagga S; Achra M; Cheng TT; Yang RS
    Osteoporos Int; 2018 Jun; 29(6):1227-1242. PubMed ID: 29460102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of fracture liaison services in osteoporosis.
    Paccou J; Philippoteaux C; Cortet B; Fardellone P
    Joint Bone Spine; 2023 Sep; 90(5):105574. PubMed ID: 37080285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
    Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
    Stevenson M; Davis S; Lloyd-Jones M; Beverley C
    Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system.
    Solomon DH; Patrick AR; Schousboe J; Losina E
    J Bone Miner Res; 2014 Jul; 29(7):1667-74. PubMed ID: 24443384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased Mortality and Subsequent Fracture Risk in Patients With a Major and Hip Fracture After the Introduction of a Fracture Liaison Service: A 3-Year Follow-Up Survey.
    Vranken L; de Bruin IJA; Driessen AHM; Geusens PPM; Eisman JA; Center JR; van der Velde RY; Janzing HMJ; Kaarsemaker S; van den Bergh JP; Wyers CE
    J Bone Miner Res; 2022 Oct; 37(10):2025-2032. PubMed ID: 36087016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network.
    Javaid MK; Sami A; Lems W; Mitchell P; Thomas T; Singer A; Speerin R; Fujita M; Pierroz DD; Akesson K; Halbout P; Ferrari S; Cooper C
    Osteoporos Int; 2020 Jul; 31(7):1193-1204. PubMed ID: 32266437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3i hip fracture liaison service with nurse and physician co-management is cost-effective when implemented as a standard clinical program.
    Beaupre LA; Lier D; Smith C; Evens L; Hanson HM; Juby AG; Kivi P; Majumdar SR;
    Arch Osteoporos; 2020 Jul; 15(1):113. PubMed ID: 32699946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.
    Svedbom A; Hadji P; Hernlund E; Thoren R; McCloskey E; Stad R; Stollenwerk B
    Osteoporos Int; 2019 Sep; 30(9):1745-1754. PubMed ID: 31270592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study.
    Cooper MS; Palmer AJ; Seibel MJ
    Osteoporos Int; 2012 Jan; 23(1):97-107. PubMed ID: 21953475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of secondary fracture prevention intervention for Medicare beneficiaries.
    Nayak S; Singer A; Greenspan SL
    J Am Geriatr Soc; 2021 Dec; 69(12):3435-3444. PubMed ID: 34343339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.